2023
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interactionPercentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use
Loya J, Babuscio T, Nich C, Alessi S, Rash C, Kiluk B. Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use. Drug And Alcohol Dependence 2023, 248: 109947. PMID: 37276806, PMCID: PMC10498479, DOI: 10.1016/j.drugalcdep.2023.109947.Peer-Reviewed Original ResearchConceptsUrine drug screensClinical trialsMeaningful endpointsCocaine useLong-term clinical benefitBetter long-term outcomesDrug screensPsychosocial functioningNegative urine drug screensLong-term outcomesRandomized clinical trialsFuture clinical trialsBetter psychosocial functioningClinical benefitPharmacological treatmentContinuous abstinenceTreatment periodTreatment respondersSustained abstinenceSubstance useTrialsTreatmentMeaningful thresholdPooled datasetAbstinence
2015
Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 2015, 18: 1002-1011. PMID: 26446070, PMCID: PMC5942618, DOI: 10.1093/ntr/ntv207.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsSmoking cessationDouble-blind placebo-controlled trialEfficacy of vareniclinePlacebo-controlled trialShort-term outcomesClinical trial dataSex differencesSimilar ratesWeek 52Week 24Women smokersNicotine replacementWeek 12Outcome endpointsTherapeutic responseClinical trialsContinuous abstinenceVarenicline's efficacyVareniclinePlacebo outcomesEqual efficacySex disparitiesEffective FDACatehol‐o‐methyltransferase gene Val158met polymorphism as a potential predictor of response to computer‐assisted delivery of cognitive‐behavioral therapy among cocaine‐dependent individuals: Preliminary findings from a randomized controlled trial
Carroll KM, Herman A, DeVito EE, Frankforter TL, Potenza MN, Sofuoglu M. Catehol‐o‐methyltransferase gene Val158met polymorphism as a potential predictor of response to computer‐assisted delivery of cognitive‐behavioral therapy among cocaine‐dependent individuals: Preliminary findings from a randomized controlled trial. American Journal On Addictions 2015, 24: 443-451. PMID: 25930952, PMCID: PMC4516567, DOI: 10.1111/ajad.12238.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyComputerized cognitive behavioral therapyVal carriersStandard treatmentCocaine-dependent individualsCocaine useStandard methadone maintenance treatmentComputer-assisted deliveryMethadone maintenance treatmentMet/Met genotypeRate of participantsSignificant treatment conditionLess cocaine useCOMT Val108/158Met polymorphismPreliminary data pointUncontrolled studiesMaintenance treatmentContinuous abstinenceTreatment outcomesTreatment responseWeek trialMet genotypePotential biomarkersBehavioral therapyVal108/158Met polymorphism
2014
Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence
Xu J, Kober H, Wang X, DeVito EE, Carroll KM, Potenza MN. Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence. Drug And Alcohol Dependence 2014, 143: 74-80. PMID: 25115748, PMCID: PMC4165405, DOI: 10.1016/j.drugalcdep.2014.07.007.Peer-Reviewed Original ResearchConceptsCocaine-dependent patientsHippocampal volumeTreatment outcomesCocaine useCocaine use severityCocaine-negative urine samplesGreater hippocampal volumePoor treatment outcomesPatient groupTreatment trialsContinuous abstinenceHigh-resolution magnetic resonance brain imagesTreatment responseIndividualized treatmentHealthy comparison individualsPatientsCocaine abstinenceCocaine dependenceBehavioral therapyCocaine-related cuesMore daysUrine samplesContingency managementSignificant differencesSignificant correlation
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounseling
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attemptsExploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug And Alcohol Dependence 2010, 112: 1-8. PMID: 20561758, PMCID: PMC2946976, DOI: 10.1016/j.drugalcdep.2010.04.021.Peer-Reviewed Original ResearchConceptsPlacebo groupStudy completersNaltrexone doseClinical trialsContinuous abstinenceOral naltrexone treatmentNicotine patch therapyNicotine replacement therapyInteractive voice responseRandomized clinical trialsMenstrual cycle statusEffect of doseNaltrexone augmentationNaltrexone groupAdverse eventsNaltrexone treatmentNicotine patchPatch therapyReplacement therapyQuit dayWeek 1AbstinenceDoseWomenLess adherent
2007
Comparing Gain- and Loss-Framed Messages for Smoking Cessation With Sustained-Release Bupropion: A Randomized Controlled Trial
Toll BA, O'Malley SS, Katulak NA, Wu R, Dubin JA, Latimer A, Meandzija B, George TP, Jatlow P, Cooney JL, Salovey P. Comparing Gain- and Loss-Framed Messages for Smoking Cessation With Sustained-Release Bupropion: A Randomized Controlled Trial. Psychology Of Addictive Behaviors 2007, 21: 534-544. PMID: 18072836, PMCID: PMC2527727, DOI: 10.1037/0893-164x.21.4.534.Peer-Reviewed Original ResearchConceptsSustained-release bupropionSmoking cessationGain-framed messagesLoss-framed messagesTreat analysisControlled TrialsPoint prevalenceClinical trialsContinuous abstinencePrevention behaviorsTreatment completersCessationBupropionExperimental groupTrialsLoss-framed conditionHigher proportionGain-framed conditionParticipantsPrevalenceA preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain
Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive Behaviors 2007, 33: 173-179. PMID: 17587504, PMCID: PMC2488403, DOI: 10.1016/j.addbeh.2007.05.012.Peer-Reviewed Original ResearchConceptsPost-cessation weight gainWeight-concerned smokersPoint prevalence abstinenceWeight gainAbstinent participantsSustained-release bupropion hydrochlorideHigher smoking cessation ratesWeight suppressant effectsOpen-label studyPercentage of patientsSmoking cessation ratesLess weight gainDays of treatmentNaltrexone augmentationAdverse eventsCombination pharmacotherapyPrimary outcomeCessation ratesTreatment regimenCigarette smokersClinical trialsContinuous abstinenceLabel studyPsychosocial interventionsBupropion
1998
Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram
Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998, 93: 713-727. PMID: 9692270, DOI: 10.1046/j.1360-0443.1998.9357137.x.Peer-Reviewed Original ResearchConceptsCognitive-behavioral treatmentAlcohol useClinical managementCocaine useConcurrent alcohol abuseDrug use disordersTreatment of cocaineCo-morbid disordersPromising treatment strategySubstance abuse treatment centersTreatment-seeking cocaine abusersUrine toxicologyDrug-dependent individualsContinuous abstinenceDisulfiram treatmentStep FacilitationTreatment strategiesCocaine-dependent individualsAlcohol abuseAlcohol abusersUse disordersTreatment centersSupportive psychotherapyAlcohol dependenceActive psychotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply